Larotaxel Dihydrate

拉洛他赛二水合物

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameLarotaxel Dihydrate
Drug Alias Name拉罗他赛二水合物LarotaxelLarotaxelum拉洛紫杉醇二水合物拉洛他赛 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin inhibitors
TargetsTubulin
Therapy Area/IndicationsMetastatic breast cancerNeoplasm MetastasisUrinary Bladder Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[40] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesSanofiBristol-Myers Squibb CompanyShanxi Zhendong Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanxi Zhendong Pharmaceutical Co Ltd
Inactive CompaniesSanofiShenyang Pharmaceutical UniversityWuxi Target Drug Research Co Ltd
Active IndicationsBreast Neoplasms
Inactive IndicationsMetastatic breast cancerNeoplasm MetastasisUrinary Bladder Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksWikipedia